Portal de Periódicos da CAPES

Anti-CD30 antibody–based therapy

2000; Lippincott Williams & Wilkins; Volume: 12; Issue: 6 Linguagem: Inglês

10.1097/00001622-200011000-00012

1531-703X

Henry Koon, Richard P. Junghans,

CAR-T cell therapy research

The increased expression of CD30 on some neoplasms versus its limited expression on normal tissue makes it an excellent target for antibody-based therapy. Recent studies have shown that anti-CD30 antibodies may serve as signaling molecules as well as mediators of interactions with the immune system. Unmodified anti-CD30 antibodies as well as anti-CD30-based bispecific antibodies, immunotoxins, and radioimmunoconjugates have been examined in preclinical and clinical studies. The data show that anti-CD30-based therapies are promising new treatment modalities for CD30+ neoplasms.